Генетические факторы наследственных фенотипов пузырно-мочеточникового рефлюкса и рефлюкс-нефропатии

Представлен обзор литературы, посвященный генетически обусловленным пузырно-мочеточниковому рефлюксу и рефлюкс-нефропатии, которые сопровождают определенные фенотипы системных или локальных форм наследственной дисплазии соединительной ткани (синдромы Элерса–Данло, Марфана, Вильямса, вялой кожи). Определена роль мутации генов фибриллярных коллагенов, эластина, трансформирующего фактора роста β1, тенасцина, лизилпероксидазы, металлопротеиназ и других компонентов соединительной ткани, а также их возможного сочетания в развитии патологии. Авторы призывают специалистов продолжать исследования генетических мутаций при пузырно-мочеточниковом рефлюксе и рефлюкс-нефропатии.

1. Williams G., Fletcher J.T., Alexander S.I., Craig J.C. Vesicoureteral reflux. J Am Soc Nephrol 2008; 19:

2. –862. DOI: 10.1681/ASN.2007020245

3. Tullus K. Vesicoureteric reflux in children. Lancet 2015; 385: 371–379. DOI: 10.1016/S0140-6736(14)60383-4

4. Fillion M.L., Watt C.L., Gupta I.R. Vesicoureteric reflux and reflux nephropathy: from mouse models to childhood disease. Pediatr Nephrol 2014; 29: 757–766. DOI: 10.1007/

5. s00467-014-2761-3

6. Tokhmafshan F., Brophy P.D., Gradegesin R.A., Gupta I.R. Vesicoureteral reflux and the extracellular matrix connection. Pediatr Nephrol 2017; 32(4): 565–576. Doi: 10.1007/s00467-016-3386-5

7. Gbadegesin R.A., Brophy P.D., Adeyemo A., Hall G., Gupta I.R., Hains D. et al. TNXB mutations can cause vesicoureteral reflux. J Am Soc Nephrol 2013; 24: 1313–1322. DOI: 10.1681/ASN.201211

8. Sjostrom S., Sillen U., Bachelard M., Hansson S., Stokland E. Spontaneous resolution of high grade infantile vesicoureteral reflux. J Urol 2004; 172: 694–698.

9. Arlen A.M., Garcia-Roig M., Weiss A.D., Leong T., Cooper C.S., Kirsch A.J. Vesicoureteral reflux index: 2-institution analysis and validation. J Urol 2016; 195(4 Pt 2): 1294–1299. DOI: 10.1016/j.juro.2015.03.094

10. Smellie J.M., Barratt T.M., Chantler C., Gordon I., Prescod N.P., Ransley P.G., Woolf A.S. Medical versus surgical treatment in children with severe bilateral vesicoureteric reflux and bilateral nephropathy: a randomised trial. Lancet 2001; 357: 1329–1333.

11. Duffield J.S. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 2014; 124: 2299–2306. DOI: 10.1172/JCI72267

12. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684–696. DOI: 10.1038/nrneph.2011.149

13. Oswald J., Schwentner C., Brenner E., Deibl M., Fritsch H., Bartsch G., Radmayr C. Extracellular matrix degradation and reduced nerve supply in refluxing ureteral endings. J Urol 2004; 172: 1099–1102.

14. Schwentner C., Oswald J., Lunacek A., Pelzer A.E., Fritsch H., Schlenck B. et al. Extracellular microenvironment and cytokine profile of the ureterovesical junction in children with vesicoureteral reflux. J Urol 2008; 180: 694–700. DOI: 10.1016/j.juro.2008.04.048

15. Radmayr C., Schwentner C., Lunacek A., Karatzas A., Oswald J. Embryology and anatomy of the vesicoureteric junction with special reference to the etiology of vesicoureteral reflux. TherAdv Urol 2009; 1: 243–250. DOI: 10.1177/1756287209348985

16. Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198–223. DOI: 10.1124/pr.109.001289

17. Agostiniani R., Mariotti P. The natural history of vesicoureteral reflux. J Matern Fetal Neonatal Med 2011; 24(Suppl 1): 2–3. DOI: 10.3109/14767058.2011.607557.

18. Lu Y., Zhang S., Wang Y., Ren X., Han J. Molecular mechanisms and clinical manifestations of rare genetic disorders associated with type I collagen. Intractable and Rare Diseases Research 2019; 8(2): 98–107. Doi: 10. 5582/irdr.2019,01064

19. Gordon M.K., Hahn R.A. Collagens. Cell Tissue Res 2010; 339: 247–257. DOI: 10.1007/s00441-009-0844-4

20. Gelse K., Poschl E., Aigner T. Collagens – structure, function, and biosynthesis. Adv Drug Deliv Rev 2003; 55: 1531–1546.

21. Wenstrup R.J., Florer J.B., Brunskill E.W., Bell S.M., Chervoneva I., Birk D.E. Type V collagen controls the initiation of collagen fibril assembly. J Biol Chem 2004; 279: 53331–53337.

22. Mouw J.K., Ou G., Weaver V.M. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol 2014; 15: 771–785. DOI: 10.1038/nrm3902

23. Liu X., Wu H., Byrne M., Krane S., Jaenisch R. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A 1997; 94: 1852–1856.

24. Brown K.L., Cummings C.F., Vanacore R.M., Hudson B.G. Building cоllagen IY smart scaffords on the outside of cells. Protein Science 2017; 26: 2151–2161. DOI: 10. 1002/pro.3283

25. Kielty C.M., Sherratt M.J., Shuttleworth C.A. Elastic fibres. J Cell Sci 2002; 115: 2817–2828.

26. Rifkin D.B. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem 2005; 280: 7409–7412.

27. Dillon M.J., Goonasekera C.D. Reflux nephropathy. J Am Soc Nephrol 1998; 9: 2377–2383.

28. Schnaper H.W., Hayashida T., Hubchak S.C., Poncelet A.C. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284: 243–252.

29. Bottinger E.P. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27: 309–320. DOI: 10.1016/j.semnephrol.2007.02.009

30. Lopez-Hernandez F.J., Lopez-Novoa J.M. Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res 2012; 347: 141–154. DOI: 10.1007/s00441-011-1275-6

31. Lethias C., Carisey A., Comte J., Cluzel C., Exposito J.Y. A model of tenascin-X integration within the collagenous network. FEBS Lett 2006; 580: 6281–6285. DOI: 10.1016/j.febslet.2006.10.037

32. Bristow J., Carey W., Egging D., Schalkwijk J. Tenascin-X, collagen, elastin, and the Ehlers–Danlos syndrome. Am J Med Genet C: Semin Med Genet 2005;139C: 24–30.

33. Egging D., van den Berkmortel F., Taylor G., Bristow J., Schalkwijk J. Interactions of human tenascin-X domains with dermal extracellular matrix molecules. Arch Dermatol Res 2007; 298: 389–396. DOI: 10.1007/s00403-006-0706-09

34. Schalkwijk J., Zweers M.C., Steijlen P.M., Dean W.B., Taylor G., van Vlijmen I.M. et al. A recessive form of the Ehlers– Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 2001; 345: 1167–1175.

35. Callewaert B., Malfait F., Loeys B., De Paepe A. Ehlers– Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol 2008; 22: 165–189. DOI: 10.1016/j.berh.2007.12.005

36. De Paepe A., Malfait F. The Ehlers–Danlos syndrome, a disorder with many faces. Clin Genet 2012; 82: 1–11. DOI: 10.1111/j.1399-0004.2012.01858.x

37. De Wandele I., Rombaut L., Malfait F., De Backer T., De Paepe A., Calders P. Clinical heterogeneity in patients with the hypermobility type of Ehlers–Danlos syndrome. Res Dev Disabil 2013; 34: 873–881. DOI: 10.1016/j.ridd.2012.11.018

38. Beiraghdar F., Rostami Z., Panahi Y., Einollahi B., Teimoori M. Vesicourethral reflux in pediatrics with hypermobility syndrome. Nephrourol Mon 2013; 5: 924–927. DOI: 10.5812/numonthly.10770

39. Robinson P.N., Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet 2000; 37: 9–25.

40. Mohamed M., Voet M., Gardeitchik T., Morava E. Cutis Laxa. Adv Exp Med Biol 2014; 802: 161–184. DOI: 10.1007/978-94-007-7893-1_11

41. Al-Hakim W., Goldsmith D.J. Bilateral popliteal aneurysms complicating adult polycystic kidney disease in a patient with a marfanoid habitus. Postgrad Med J 2003; 79: 474–475.

42. Stromme P., Bjornstad P.G., Ramstad K. Prevalence estimation of Williams syndrome. J Child Neurol 2002; 17: 269–271.

43. Pober B.R. Williams-Beuren syndrome. N Engl J Med 2010; 362: 239–252. DOI: 10.1056/NEJMra0903074